유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

accord healthcare s.l.u. - buprenorphine hydrochloride, naloxone hydrochloride dihydrate - opioid-relaterede lidelser - andre narkotika stoffer - substitutionsbehandling for opioidlægemiddelafhængighed inden for rammerne af medicinsk, social og psykologisk behandling. intentionen med naloxon-komponenten er at afskrække intravenøs misbrug. behandlingen er beregnet til brug hos voksne og unge over 15 år, som har accepteret at blive behandlet for afhængighed.

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

hameln pharma gmbh - amiodaronhydrochlorid - koncentrat til injektions-/infusionsvæske, opløsning - 50 mg/ml

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - buspironhydrochlorid - tabletter - 10 mg

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

hameln pharma gmbh - oxycodonhydrochlorid - injektions-/infusionsvæske, opløsning - 10 mg/ml

유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - daunorubicin hydrochloride, cytarabine - leukæmi, myeloid, akut - antineoplastiske midler - vyxeos liposomal er indiceret til behandling af voksne med nyligt diagnosticeret, terapi-relateret akut myeloid leukæmi (t-aml) eller aml med myelodysplastisk-relaterede ændringer (aml-mrc).

유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

lupin europe gmbh - mexiletine hydrochloride - myotonic lidelser - hjertetapi - namuscla er indiceret til symptomatisk behandling af myotonia i voksne patienter med ikke-dystrofiske myotonic lidelser.

덴마크 - 덴마크어 - Lægemiddelstyrelsen (Danish Medicines Agency)

kalceks as - oxycodonhydrochlorid - injektions-/infusionsvæske, opløsning - 10 mg/ml

유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - stråling skader - detoxifying agents for antineoplastic treatment - lysakare er indiceret til reduktion af nyre-stråling i løbet af peptid-receptor radionuklid terapi (prrt) med lutetium (177lu) oxodotreotide i voksne.

유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

유럽 연합 - 덴마크어 - EMA (European Medicines Agency)

ucb pharma s.a.   - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptika, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.